• Journal of Oral Medicine and Pain
• /
• v.41 no.4
• /
• pp.195-199
• /
• 2016

Central sensitization represents a functional change of second order neuron induced by continuous deep pain input and maintained by psychosocial factors. When afferent neurons are involved with central sensitization, secondary hyperalgesia can appear. Secondary hyperalgesia is an increased sensitivity to stimulation without a local cause. Reports on secondary hyperalgesia to heat stimuli are relatively rare compared to mechanical stimuli. And there were few reports of secondary hyperalgesia to heat stimuli in the oral cavity. We presented a case of secondary hyperalgesia to heat stimuli in the gingival area induced by continuous odontogenic pain with a review of the related literature.

• Journal of Oral Medicine and Pain
• /
• v.41 no.2
• /
• pp.72-75
• /
• 2016

Lichen planus is a chronic disease characterized by bilateral and multiple lesions on the skin or oral mucosa. Lichen planus is caused by immune mediated degeneration along the border between epithelium and connective tissue. The incidence of oral squamous cell carcinoma in patients diagnosed with oral lichen planus (OLP) is reported to be between 0.4%-5.6% in different studies and the World Health Organization has categorized lichen planus as "a potentially malignant disorder". However, the correlation between OLP and oral cancer still remains controversial as some reported that the reason for increased incidence of squamous cell carcinoma in OLP patient is misdiagnosis of dysplastic lesion as OLP. This report aims to discuss the correlation between OLP and oral cancer through a case of middle aged woman diagnosed with OLP who was successfully treated but developed squamous cell carcinoma 8 years later.

• Journal of Oral Medicine and Pain
• /
• v.20 no.1
• /
• pp.127-131
• /
• 1995

A patient who showed atypical orofacial pain after an endodontic treatment for a long time, was treated with non-analgesics such as vitamin $B_1, B_2, $ and Oral Balance, moisturizing gel. 1. It is important to manage xerostomic condition properly in the treatment of patients who have atypical orofacial pain 2. Simultaneous administration of vitamin $B_1 and B_2$ was effective in increasing pain threshold of the patient.

• Journal of Oral Medicine and Pain
• /
• v.45 no.4
• /
• pp.110-114
• /
• 2020

Myofascial pain (MFP) is one of the most common causes of persistent orofacial pain. Patients with chronic myofascial orofacial pain may present with diffuse heterotopic pain, complicating the correct diagnosis. Treatment of chronic MFP should focus on the elimination of aetiologic factors. This article describes two cases of chronic MFP of the masticatory muscles, whose symptoms were exacerbated after masseteric nerve neurectomy. The patients had suffered from irrelevant treatment which did not resolve the symptom. Their symptom was managed by conventional treatment protocol. These cases emphasize the importance of correct diagnosis and evidence-based approach.

• Journal of Dental Anesthesia and Pain Medicine
• /
• v.19 no.2
• /
• pp.77-82
• /
• 2019

It is well known that trigeminal nerve injury causes hyperexcitability in trigeminal ganglion neurons, which become sensitized. Long after trigeminal nerve damage, trigeminal spinal subnucleus caudalis and upper cervical spinal cord (C1/C2) nociceptive neurons become hyperactive and are sensitized, resulting in persistent orofacial pain. Communication between neurons and non-neuronal cells is believed to be involved in these mechanisms. In this article, the authors highlight several lines of evidence that neuron-glial cell and neuron macrophage communication have essential roles in persistent orofacial pain mechanisms associated with trigeminal nerve injury and/or orofacial inflammation.

• Journal of Oral Medicine and Pain
• /
• v.35 no.3
• /
• pp.221-227
• /
• 2010

MyoFascial Pain Syndrome(MFPS) is defined as a regional pain syndrome characterized by muscle pain caused by myofascial trigger points (MTrPs). Myofascial pain is a common cause of persistent regional pain such as neck pain, shoulder pain, headaches, and orofacial pain. Clinicians who deal with orofacial pain must also understand the role of myofascial pain. This case report presents the treatment of botulinum toxin A for chronic myofascial pain.

• Biomedical Science Letters
• /
• v.26 no.4
• /
• pp.327-335
• /
• 2020

As the interest in oral health is increasing with quality of life. The most representative oral diseases include dental caries, periodontal disease, and malocclusion, as well as dry mouth and oral mucosa. Cinnamaldehyde have an antioxidant effect that has been studied not only to treat rheumatism and hypertension, but also to protect liver, and gastrointestinal tract, but there are few studies related to the control of oral diseases. The purpose of this study was the effect of enhanced orofacial pain when oral administration of cinnamaldehyde in the oral diseases. Cinnamaldehyde (5, 12.5, 25, and 50 mg/kg) orally administered at a dose of 1 mL, and the change in biological response was confirmed after a week. In addition, 5% formalin (30, 50 μL) was injected into TMJ and subcutaneous areas of the whiskers of rats to observe the change in the threshold of the improved orofacial pain model. As a result of the experiment, in the xerostomia model, drinking water was decreased in the cinnamaldehyde-administered group, feed intake and weight increased, and saliva was also increased compared to the naïve group. In particular, the most significant increase trend was observed at the concentrations of 25 and 50 mg/kg. In addition, it was confirmed that the pain behavioral response of the orofacial area improved by oral diseases decreased depending on the concentration of cinnamaldehyde. Based on these results, cinnamaldehyde effectively reduced symptoms related to xerostomia and showed improved pain relief in the orofacial areas.

• Journal of Oral Medicine and Pain
• /
• v.49 no.1
• /
• pp.3-4
• /
• 2024

• Biomedical Science Letters
• /
• v.24 no.3
• /
• pp.239-244
• /
• 2018

Recently, many researches regarding the natural products which alternate with chemical products have been done. Among them, boswellia is well known for effect on anti-oxidative effect and inflammation. The aim was the effect boswellia of formalin- induced orofacial and temporomandibular joint (TMJ) pain on experimental animals was investigated. Experiments were carried out using subcutaneous (SC) pain model and TMJ pain model that were induced by the injection of 5% formalin into the right vibrissa pad (SC, $50{\mu}L$) or TMJ ($30{\mu}L$) of rats, respectively. In both models, formalin (5%), formalin after distilled water (vehicle), formalin after boswellia extract (p.o., concentrations of 15, 30 mg/kg) (n=6). The number of scratching on the injected region was scored during the 9 successive periods of 5 min intervals following injection of formalin. Oral administration of boswellia (15, 30 mg / kg) reduced formalin-induced SC orofacial pain behavioral responses. SC orofacial pain behavioral responses was significantly reduced at 20~35 min. In the experimental group injected into temporomandibular joints, the pain response was significantly reduced by $276.2{\pm}8.20$ and $78.3{\pm}4.7$ after oral administration of boswellia (15, 30 mg / kg) at $398.3{\pm}24.8$ times. As a result of the passage of time, the oral administration of boswellia showed a significant effect of reducing the temporomandibular joint pain 30 minutes after the injection of formalin. This study confirmed that oral administration of boswellia modulated the pain behavior in both models. In conclusion, boswellia extract may be a potential therapeutic treatment for orofacial pain.

• Maxillofacial Plastic and Reconstructive Surgery
• /
• v.40
• /
• pp.21.1-21.5
• /
• 2018

Background: The purpose of this study was to evaluate the clinical outcomes of treatment of non-odontogenic atypical orofacial pain using botulinum toxin-A. Methods: This study involved seven patients (seven females, mean age 65.1 years) who had non-odontogenic orofacial pain (neuropathic pain and atypical orofacial pain) and visited the Seoul National University Bundang Hospital between 2015 and 2017. All medication therapies were preceded by botulinum toxin-A injections, followed by injections in the insignificant effects of medication therapies. Five of the seven patients received intraoral injections in the gingival vestibule or mucosa, while the remaining two received extraoral injections in the masseter and temporal muscle areas. Results: In five of the seven patients, pain after botulinum toxin-A injection was significantly reduced. Most of the patients who underwent surgery for dental implantation or facial nerve reconstruction recovered after injections. However, the pain did not disappear in two patients who reported experiencing persistent pain without any cause. Conclusions: The use of botulinum toxin-A for the treatment of non-odontogenic neuropathic orofacial pain is clinically useful. It is more effective to administer botulinum toxin-A in combination with other medications and physical therapy to improve pain.